Douglas A Drevets, MD, DTM&H, FIDSA

Drevets Bio


Dr. Drevets is a physician scientist with expertise in neuro-infection/neuro-inflammation and in clinical infectious diseases including treatment of patients with HIV/AIDS. His current positions are a Regents’ Professor and Chief of of Infectious Diseases, and Vice Chair for Faculty Affairs in the Dept. of Internal Medicine at the Oklahoma University Health Sciences Center (OUHSC). He also holds an appointment as a Staff Physician at the Oklahoma City Veterans Affairs Medical Center (VAMC).


Dr. Drevets received his M.D. from the University of Kansas School of Medicine, completed his residency in Internal Medicine at the Indiana University Medical Center and his sub-specialty training in Infectious Diseases at the University of Colorado HSC, Denver, CO. He is board certified in Internal Medicine and in Infectious Diseases.  In a typical academic year, Dr. Drevets spends approximately 40% of his time in direct patient care and clinical teaching.  Inpatient venues include the Adult Tower of OUMC and the Oklahoma City VAMC.  Ambulatory care of patients with HIV/AIDS is performed at the Infectious Diseases Institute of OUHSC.  He has been the site Medical Director for the components of the AETC program housed at OUHSC for 10 years and is active in educating learners of all type about HIV/AIDS.


Dr. Drevets science background lies in the areas of monocyte biology, host defenses to infection with intracellular bacteria, and pathogenesis of central nervous system infections. He has a long-standing interest in pathogenesis of infections caused by Listeria monocytogenes, a neuroinvasive bacterial pathogen.   Work in his laboratory is directed at finding novel means to limit brain inflammation during antibiotic treatment of L. monocytogenes infection in mice. Currently, he is evaluating the role of microRNA-155 in the brains of infected mice and is testing the extent to which reducing its expression benefits host recovery. He is the corresponding PI on an NIH-funded project in neurocysticercosis, a helminthic infection of the brain. Along with collaborators, he is investigating monocyte mRNA transcripts as a novel diagnostic modality in patients with neurocysticercosis.  The clinical site for this project is in the Vellore district of Tamil Nadu, India with laboratory components performed by collaborators in South India (Bengaluru and Vellore) as well as at OUHSC. He has also been involved as one of the Principal Investigators on a Hepatitis C elimination project in the Cherokee Nation in northeastern Oklahoma funded by the Gilead Foundation.